Shanghai, Suzhou, Chengdu, China — November 5, 2025 — Immunofoco Biotech announced that preclinical data for IMV103 (iMagic-18.2), its In Vivo generated CLDN18.2-targeted CAR-T therapy, has been selected for a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) conference “Breakthroughs in Targeted In Vivo Gene Editing.” The meeting will be held November 20-21, 2025, in San Diego, California, USA.
Autologous CAR-T cell therapy has made significant progress in hematologic malignancies and shown promise in solid tumors. However, the complex manufacturing process and high costs have limited its broader application. To address these challenges, we developed the iMagic platform, a novel lentiviral-based in vivo CAR-T system incorporating a mutated MxV glycoprotein and a T cell-targeting module (TCM3). This platform enables selective transduction of T cells and direct generation of CAR-T cells in vivo and has demonstrated potent antitumor efficacy in blood cancer models. Here, we present the preclinical data of in vivo generated CLDN18.2 CAR-T (IMV103) in gastric cancer models.
Poster Presentation Details:
Title: Preclinical efficacy and safety profile of in vivo generated claudin 18.2 specific chimeric antigen receptor t cells in gastric cancer models
Date: Thursday, November 20th
Poster Viewing and Reception: 5-6:30 p.m. PT
Venue: San Diego, CA
About Immunofoco
Immunofoco has pioneered a clinical strategy focused on "curing the solid tumors by treating them as hematologic malignancies", addressing the challenges in solid tumor treatment, and the clinical advantages of treating hematologic malignancies. To improve the safety of CAR-T products, counteract tumor heterogeneity, and to enhance their effectiveness in tumor amplification and infiltration, we have developed innovative platforms such as Peri Cruiser®, SNR, T-Booster and In Vivo. Driven by the clinical outcomes, our company maintains an extensive spectrum of product pipelines. Notably, IMC002, a CLDN18.2-targeted CAR-T therapy, has progressed to a Phase III pivotal trial in China. This follows its IND approvals from both U.S. and Chinese authorities in April 2023, and it holds U.S. FDA Fast Track designation along with Orphan Drug Designations for both gastric and pancreatic cancer. Similarly, our IMC001 (EpCAM CAR-T) product obtained ODD from the U.S. FDA in August 2023, and its IND application has been approved in both the U.S. and China in February 2024, followed by the approval of a second IND in China in March 2025. The IMC008 (SNR CAR-T) product has rapidly moved to the IIT stage and received two ODD approvals from the U.S. FDA in August 2023, for the treatment of gastric cancer and pancreatic cancer, respectively. Embodying the ethos of "collaboration, aspiration, and dedication for the best clinical results," our company brings together industry talents and experts to develop innovative cell therapies that offer enduring survival benefits for patients with solid tumors. For further details about Immunofoco, please visit our website at www.immunofoco.com.
